Clinical benefits shown with pembrolizumab plus chemotherapy regardless bevacizumab use in advanced or recurrent cervical cancer
Findings are from an exploratory subgroup analysis of the KEYNOTE-826
Long-term follow up data confirms the benefits of perioperative pembrolizumab in early-stage NSCLC
In the KEYNOTE-671, improvements in event-free survival and overall survival were observed after four years of follow up
Neoadjuvant pembrolizumab plus chemotherapy increases pathological complete response in high-risk early breast cancer
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Tiragolumab plus atezolizumab failed to improve overall survival in advanced non-squamous NSCLC
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
An oncolytic adenovirus shows promise in inducing immune response in prostate cancer
Early-phase data suggest that intratumour injections of ORCA-010 may convert cold tumours into immunogenic ones
ctDNA and beyond to serve immunotherapy
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed
Sacituzumab govitecan failed to improve overall survival in pre-treated urothelial carcinoma
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Mixed results for additional immunotherapy to standard care in stage III NSCLC
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Next steps for research include personalising regimens and learning how to predict response and toxicity
New data show promise in using liquid biopsies to tailor immunotherapy
Studies explore the prognostic and predictive values of circulating DNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells